SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on March 18, 2020, covering events occurring on March 17, 2020. The registrant is a Delaware corporation trading on the Nasdaq Capital Market under the symbol "CERC" and is classified as an Emerging Growth Company.
Key Financial Metrics
The filing details a private placement transaction rather than periodic financial results. Key metrics from the transaction include:
- Shares Sold: 1,951,219 shares of Common Stock.
- Purchase Price: $2.05 per share (closing price on March 17, 2020).
- Gross Proceeds: Approximately $4,000,000.
- Net Proceeds: Approximately $3,900,000.
- Use of Proceeds: General corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement with funds associated with Armistice Capital, LLC, a significant stockholder. This transaction resulted in the issuance of new equity and an increase in the company's cash position by approximately $3.9 million in net proceeds.
Outlook, Risks, and Agreements
In connection with the sale, the Company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of the shares within 60 days of the closing date. The transaction was conducted under Section 4(a)(2) of the Securities Act of 1933 as an exemption from registration. The filing explicitly states it is not an offer to sell or a solicitation of an offer to buy securities.
Investor Verification Checklist
- Verify the identity of the investor (Armistice Capital, LLC) and their existing stake in the company.
- Confirm the dilution impact of the 1,951,219 newly issued shares on existing shareholders.
- Review the attached Exhibits 10.1 and 10.2 for specific terms of the Securities Purchase and Registration Rights Agreements.
- Monitor the filing of the registration statement for resale within the mandated 60-day window.